Markus Warmuth is CEO & President at Monte Rosa Therapeutics, Inc. (GLUE). They have made 4 open-market trades across 1 company since 2026, most recently 2026-07-16.
CIK 0001855643
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GLUE | 585,038 | $5.7M |
Shares reported on the most recent Form 4, priced at the 2026-07-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GLUE | SELL | 2026-07-16 | 2026-07-17 | $23.18 | $220K | -14.0% | -38.7% | -59.6% |
| GLUE | SELL · 10b5-1 | 2026-06-01 | 2026-06-02 | $19.44 | $106K | +3.6% | +37.5% | -20.8% |
| GLUE | SELL · 10b5-1 | 2026-05-01 | 2026-05-05 | $18.92 | $103K | -6.9% | -10.9% | -21.2% |
| GLUE | SELL | 2026-04-14 | 2026-04-15 | $17.64 | $141K | +6.0% | -0.2% | +29.0% |
| GLUE | SELL · 10b5-1 | 2026-03-02 | 2026-03-04 | $17.92 | $98K | -9.8% | -6.6% | -2.2% |
| GLUE | SELL | 2026-01-07 | 2026-01-09 | $23.49 | $128K | -4.3% | -18.6% | -25.0% |
| GLUE | SELL | 2026-01-05 | 2026-01-05 | $15.17 | $154K | +69.9% | +37.8% | +19.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.